Dr. Joseph Sokhn
Claim this profileSaint Luke's Hospital
Expert in Cancer
Studies Lung Cancer
28 reported clinical trials
87 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
HER2 positive
Stage II
2Lung Cancer
Stage IV
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Joseph Sokhn is currently running
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting1 award Phase 227 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Joseph Sokhn
Clinical Trial Related5 years of experience running clinical trials · Led 28 trials as a Principal Investigator · 18 Active Clinical TrialsTreatments Joseph Sokhn has experience with
- Nivolumab
- Ipilimumab
- Paclitaxel
- Carboplatin
- Biospecimen Collection
- Pembrolizumab
Breakdown of trials Joseph Sokhn has run
Cancer
Lung Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Joseph Sokhn specialize in?
Joseph Sokhn focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Joseph Sokhn currently recruiting for clinical trials?
Yes, Joseph Sokhn is currently recruiting for 17 clinical trials in Chesterfield Missouri. If you're interested in participating, you should apply.
Are there any treatments that Joseph Sokhn has studied deeply?
Yes, Joseph Sokhn has studied treatments such as Nivolumab, Ipilimumab, Paclitaxel.
What is the best way to schedule an appointment with Joseph Sokhn?
Apply for one of the trials that Joseph Sokhn is conducting.
What is the office address of Joseph Sokhn?
The office of Joseph Sokhn is located at: Saint Luke's Hospital, Chesterfield, Missouri 63017 United States. This is the address for their practice at the Saint Luke's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.